Dichloropane

Uncontrolled hypertension, Recent myocardial infarction, Heart failure, Clinically significant arrhythmias

Dichloropane's potent inhibition of dopamine and norepinephrine reuptake elevates catecholaminergic tone, producing dose-dependent tachycardia, hypertension, and vasoconstriction. In individuals with severe cardiovascular disease, these effects pose risk of acute coronary syndrome, hypertensive emergency, or arrhythmia exacerbation.

Individuals with epilepsy or other seizure disorders face elevated risk of breakthrough seizures. Stimulant-class compounds including cocaine analogs lower the seizure threshold dose-dependently. No seizure data specific to dichloropane exist.

Schizophrenia, Schizoaffective disorder, Bipolar disorder with psychotic features

Dichloropane's potent DAT inhibition elevates synaptic dopamine in pathways implicated in psychosis. Individuals with psychotic spectrum conditions face elevated risk of symptom exacerbation or acute psychotic episodes.

NET and DAT inhibition produce sympathetic hyperarousal that can trigger or worsen anxiety symptoms, including panic attacks, in predisposed individuals.

Pheochromocytoma produces excess endogenous catecholamines. Dichloropane's DAT and NET inhibition prevents catecholamine reuptake, compounding the existing catecholamine excess and risking hypertensive crisis.

Hyperthyroidism produces a state of sympathetic hyperactivation. Dichloropane's catecholaminergic potentiation compounds this effect, increasing risk of tachycardia, hypertension, and cardiac arrhythmias.

No reproductive toxicity, teratogenicity, or lactation transfer data exist for dichloropane. Stimulant-class compounds are generally contraindicated in pregnancy due to cardiovascular stress, potential uteroplacental vasoconstriction, and unknown fetal effects.

Concurrent use of dichloropane with any monoamine oxidase inhibitor (irreversible: phenelzine, tranylcypromine; selective MAO-B at supratherapeutic doses: selegiline) is contraindicated due to risk of serotonin syndrome. Dichloropane's potent SERT inhibition (IC₅₀ 3.13 nM) combined with MAO inhibition prevents both reuptake and degradation of serotonin, producing dangerous synaptic serotonin accumulation.

SSRIs (fluoxetine, sertraline, paroxetine), SNRIs (venlafaxine, duloxetine), Triptans, Tramadol

Dichloropane is a potent SERT inhibitor (IC₅₀ 3.13 nM). Co-administration with other serotonergic medications produces additive serotonin reuptake inhibition, increasing the risk of serotonin syndrome — a potentially life-threatening condition characterized by hyperthermia, rigidity, and autonomic instability.